Actinium Pharmaceuticals, Inc.
ATNM
$1.71
$0.074.27%
AMEX
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -70.64% | 231.77% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -54.90% | 121.69% | |||
| Operating Income | 54.90% | -121.69% | |||
| Income Before Tax | 56.85% | -139.60% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 56.85% | -139.60% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 56.85% | -139.60% | |||
| EBIT | 54.90% | -121.69% | |||
| EBITDA | 55.58% | -120.48% | |||
| EPS Basic | 56.84% | -139.63% | |||
| Normalized Basic EPS | 56.84% | -139.71% | |||
| EPS Diluted | 56.84% | -139.63% | |||
| Normalized Diluted EPS | 56.84% | -139.71% | |||
| Average Basic Shares Outstanding | 0.00% | -0.03% | |||
| Average Diluted Shares Outstanding | 0.00% | -0.03% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||